Vaxcyte Inc (PCVX) — Cash Flow-to-Debt Ratio
Vaxcyte Inc (PCVX) has a Cash Flow-to-Debt Ratio of -0.80x as of March 2026, meaning its operating cash flow of $-280.62 Million could theoretically repay -1% of its total liabilities ($352.29 Million) in one year. See Vaxcyte Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vaxcyte Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Vaxcyte Inc across 9 annual periods. Also explore Vaxcyte Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vaxcyte Inc (2017–2025)
Year-by-year debt coverage analysis for Vaxcyte Inc. For market capitalisation and broader financial context, see Vaxcyte Inc (PCVX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.82x | $-655.58 Million | $360.45 Million | ▲ +17.4% |
| 2024 | -2.20x | $-452.63 Million | $205.50 Million | ▼ -24.3% |
| 2023 | -1.77x | $-296.79 Million | $167.45 Million | ▲ +45.4% |
| 2022 | -3.25x | $-170.60 Million | $52.56 Million | ▼ -7.8% |
| 2021 | -3.01x | $-121.39 Million | $40.32 Million | ▼ -203.4% |
| 2020 | -0.99x | $-46.63 Million | $46.98 Million | ▼ -262.2% |
| 2019 | -0.27x | $-47.15 Million | $172.07 Million | ▼ -15.6% |
| 2018 | -0.24x | $-30.47 Million | $128.53 Million | ▼ -13670.9% |
| 2017 | 0.00x | $-14.96K | $8.69 Million | — |